The overarching goal of this ambitious program project continues to be to develop innovative, transformative statistical methods for cancer clinical trials that have the potential to hasten successful introduction of new therapies and treatment strategies into practice. Advances in the biologic, genomic, statistical, and computational sciences hold great promise for the development of personalized cancer treatments. Our multi-institutional, interdisciplinary team of investigators will leverage these advances to create new clinical trial designs and data analysis approaches that resolve many of the key limitations of current statistical methods and that maximize the effectiveness of clinical trials for personalized cancer medicine. In addition, we will foster translation of these methods into practice, including carrying out pilot animal and human studies based on the new methodology. The program will achieve these objectives through five, interrelated research projects carried out by investigators with complementary expertise in the statistical, computational, and clinical sciences from three institutions. The first four projects focus on developing new trial designs and analysis methods that integrate biomarkers for efficient discovery of new, personalized treatments; on creating methods for analysis of existing data on biomarkers and patient reported outcomes to inform and improve the design of future studies; developing methods for maximizing the power of pharmacogenomics for identifying biomarkers and candidate individualized therapies; and creating new methods for discovering and validating sequential, personalized decision-making strategies for cancer treatment. The fifth project will integrate the methods into novel preclinical and clinical studies of pancreatic cancer. Our comprehensive approach involves an energetic and coordinated process for implementation, communication, and dissemination of results, including development of professional, public-use software and associated tutorials; workshops and other outreach mechanisms; and program-sponsored symposia and events, to accelerate the adoption of the methods in practice. The proposed clinical trial design and analysis innovations have the potential to effect a paradigm shift in the way cancer clinical trials are conducted for discovery and validation of personalized medicine. This comprehensive, multi-institutional effort will lead to significant innovations in cancer clinical trial practice that will result in improved health of cancer patients.
This program project is focused on the development of new methods for cancer clinical trials that have the potential to accelerate the discovery of effective new cancer treatments and strategies for personalizing cancer therapy to the unique features of individual patients. The methods will be of great importance to public health, as almost all advances in cancer treatment must pass through the clinical trial process before being adopted in clinical practice.
|Chen, Stephanie T; Xiao, Luo; Staicu, Ana-Maria (2018) A Smoothing-based Goodness-of-Fit Test of Covariance for Functional Data. Biometrics :|
|Davenport, Clemontina A; Maity, Arnab; Sullivan, Patrick F et al. (2018) A Powerful Test for SNP Effects on Multivariate Binary Outcomes using Kernel Machine Regression. Stat Biosci 10:117-138|
|Wang, Lan; Zhou, Yu; Song, Rui et al. (2018) Quantile-Optimal Treatment Regimes. J Am Stat Assoc 113:1243-1254|
|Chen, Kun; Mishra, Neha; Smyth, Joan et al. (2018) A Tailored Multivariate Mixture Model for Detecting Proteins of Concordant Change Among Virulent Strains of Clostridium Perfringens. J Am Stat Assoc 113:546-559|
|Lachos, Victor H; A Matos, Larissa; Castro, Luis M et al. (2018) Flexible longitudinal linear mixed models for multiple censored responses data. Stat Med :|
|Hager, Rebecca; Tsiatis, Anastasios A; Davidian, Marie (2018) Optimal two-stage dynamic treatment regimes from a classification perspective with censored survival data. Biometrics :|
|Kong, Dehan; Ibrahim, Joseph G; Lee, Eunjee et al. (2018) FLCRM: Functional linear cox regression model. Biometrics 74:109-117|
|Sun, Wei; Bunn, Paul; Jin, Chong et al. (2018) The association between copy number aberration, DNA methylation and gene expression in tumor samples. Nucleic Acids Res 46:3009-3018|
|Lin, Jiaxing; Gresham, Jeremy; Wang, Tongrong et al. (2018) bcSeq: an R package for fast sequence mapping in high-throughput shRNA and CRISPR screens. Bioinformatics 34:3581-3583|
|Wu, Jing; de Castro, Mário; Schifano, Elizabeth D et al. (2018) Assessing covariate effects using Jeffreys-type prior in the Cox model in the presence of a monotone partial likelihood. J Stat Theory Pract 12:23-41|
Showing the most recent 10 out of 549 publications